News >

Axillary Lymph Node Dissection Can Be Avoided for Some Patients With Breast Cancer, Study Shows

Allie Casey
Published: Monday, Dec 19, 2016

Jean-Marc Classe, MD, PhD

Jean-Marc Classe, MD, PhD

Results of a clinical trial show that an axillary lymph node dissection (ALND) can be avoided for patients with large, operable tumors in the breast, no clinical signs of cancer in the axillary nodes before being treated with neoadjuvant chemotherapy, and no signs of cancer following a sentinel lymph node biopsy (SLNB) during surgery. These findings were presented at the 2016 San Antonio Breast Cancer Symposium.

Longer follow-up of the patients is needed, Classe said, to further confirm the safety of SLNB in these patients.
Classe JM, Loaec C, Alran S, et al. Sentinel node detection after neoadjuvant chemotherapy in patient without previous axillary node involvement (GANEA 2 trial): follow-up of a prospective multi-institutional cohort. Presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Abstract S2-07.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication